Clinical Trial: A Long-term Trial of EB-1020 in Pediatric Patients With ADHD

U.S., July 29 -- ClinicalTrials.gov registry received information related to the study (NCT07087327) titled 'A Long-term Trial of EB-1020 in Pediatric Patients With ADHD' on July 24.

Brief Summary: The purpose of this study is to evaluate the safety of long-term administration of mainly high doses of EB-1020 over 52 weeks in pediatric ADHD patients.

Study Start Date: Aug., 2025

Study Type: INTERVENTIONAL

Condition: Attention-Deficit Hyperactivity Disorder(ADHD)

Intervention: DRUG: EB-1020 (Centanafadine) low dose

low dose, capsule, oral, once daily, for 52 weeks

DRUG: EB-1020 (Centanafadine) high dose

high dose, capsule, oral, once daily, for 52 weeks

Recruitment Status: RECRUITING

Sponsor: Otsuka Pharmaceutical Co., Ltd.

Discl...